Prostate Cancer News and Research

Latest Prostate Cancer News and Research

LCA calls for comprehensive plan of action to reduce lung cancer mortality

Lung Cancer Alliance called again today for a comprehensive plan of action that will make reducing lung cancer mortality a public health priority.

2 Apr 2011

University of Houston part of multi-investigator $5.2M CPRIT award for prostate cancer research

A pair of University of Houston (UH) researchers and their colleagues will begin work to develop new methods for treating the most severe form of prostate cancer thanks to $5.2 million in grants recently awarded by the Cancer Prevention and Research Institute of Texas (CPRIT).

2 Apr 2011

Lilly's Axiron testosterone replacement therapy now available in US pharmacies

Eli Lilly and Company announced today that Axiron® (testosterone) topical solution is available in pharmacies throughout the United States. Axiron is a prescription medicine used to treat adult males that have low or no testosterone. Safety and efficacy of Axiron in males younger than 18 years of age have not been established.

1 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

Analysis of non-tumor tissue may be an effective option for diagnosis of prostate cancer

Researchers have found that it may not be necessary to look for tumors directly in patients with prostate cancer - analyzing non-tumor tissue may be an effective option, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.

1 Apr 2011

Medicare moves to pay for Provenge

On Wednesday, Medicare officials signaled the federal insurance program will pay for this costly prostate cancer drug, a move that National Journal described as heading off "accusations that the [government] would be 'rationing' care."

1 Apr 2011

Mitomics introduces new test to detect prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, announced today the launch of its flagship product, the Prostate Core Mitomic Test, a revolutionary new test that uses the science of mitochondrial DNA to accurately determine the absence or presence of cancerous cells using previously obtained prostate biopsy tissue.

1 Apr 2011

First Edition: March 31, 2011

In today's news, reports on continuing congressional efforts to reach a deal on the current-year budget and on a move by Medicare to cover Provenge, a prostate cancer drug.

31 Mar 2011

Protox reports net loss of $4.5 million for year ended December 31, 2010

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the year ended December 31, 2010.

31 Mar 2011

Researchers identify drug candidate that can treat prostate cancer

The best way to prevent the lethal spread of prostate cancer is by stopping cancer cell invasion of other tissues. Available treatments such as chemotherapy are toxic and can often be risky for older men, who are also most likely to get prostate cancer.

31 Mar 2011

Prostate cancer drug and a new drug to prevent preterm births cause cost concerns, controversy

News outlets report on the political dilemma involved with Provenge — a cancer drug — as well as the impact that Makena — the medicine that can prevent preterm births — could have on the nation's high health care costs.

30 Mar 2011

Prostate Oncology Specialists introduces new blog for patients

Prostate Oncology Specialists, Inc. announces the launch of the "Prostate Snatchers" blog. It features contributions from a medical oncologist, Mark Scholz MD, who specializes only in prostate cancer and a prostate cancer patient, Ralph H. Blum.

30 Mar 2011

Smoking withdrawal after liver transplantation may protect against neoplasia development

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies than patients who keep smoking.

30 Mar 2011

Smoking cessation after liver transplantation reduces incidence of malignancy

Spanish researchers have found that liver transplant recipients who quit smoking have a lower incidence of smoking-related malignancies (SRM) than patients who keep smoking. In fact, SRMs were identified in 13.5% of deceased patients and smoking was associated with a higher risk of malignancy in this study. Full findings are published in the April issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

29 Mar 2011

New study: Many elderly men may overuse PSA testing

A new study on the use of prostate-specific antigen-based prostate cancer screening in the United States found that many elderly men may be undergoing unnecessary prostate cancer screenings.

29 Mar 2011

CytRx to present bafetinib preclinical study results at AACR Annual Meeting

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies demonstrating that its oncology drug candidate bafetinib inhibits bone destruction in model systems is being presented on April 2, 2011 at the American Academy for Cancer Research 102nd Annual Meeting in Orlando, Florida.

29 Mar 2011

Prostate cancer updates

A Hunter-based prostate cancer support group says ground-breaking research by the University of Newcastle will help save many lives in the region. This new work has found patients with localized advanced prostate cancer can double their chances of survival by undertaking hormone therapy in combination with radiology treatment. This comes from a 10 year trial, coordinated by the University's Professor Jim Debnam.

28 Mar 2011

Dosing commences in Phase I clinical study of GenSpera's G-202 at Cancer Therapy & Research Center

GenSpera, Inc. announced that the first patient was dosed in the ongoing Phase I clinical study of its chemotherapeutic agent, G-202, at the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio in San Antonio, Texas.

28 Mar 2011

FDA approves ipilimumab for metastatic melanoma treatment

The U.S. Food and Drug Administration announced today its approval of a new treatment for advanced melanoma, the deadliest and most difficult-to-treat form of skin cancer.

28 Mar 2011

CPRIT awards Bellicum $5.7 million to advance CaspaCIDe therapy for late stage cancer

Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program.

25 Mar 2011